Atovaquone plus cholestyramine in patients coinfected with Babesia microti and borrelia burgdorferi refractory to other treatment

Advances in Therapy

Volumn 23, Issue 1, 2006, Pages 1-11

  Shoemaker, Ritchie C ^a   Hudnell, H Kenneth ^b   House, Dennis E ^a   Van Kempen, Amy ^c   Pakes, Gary E ^c  

^a Center for Research on Biotoxin Associated Illnesses   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Atovaquone; Babesiosis; Cholestyramine; Lyme disease; Visual contrast sensitivity

Indexed keywords

AMOXICILLIN; ATOVAQUONE; AZITHROMYCIN; CEFUROXIME; COLESTYRAMINE; DOXYCYCLINE; PLACEBO;

ADULT; ARTICLE; BABESIA MICROTI; BABESIOSIS; BORRELIA BURGDORFERI; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LONG TERM CARE; LYME DISEASE; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANION EXCHANGE RESINS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; BABESIA MICROTI; BABESIOSIS; CHOLESTYRAMINE; CONTRAST SENSITIVITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LYME DISEASE; MALE; MIDDLE AGED; NAPHTHOQUINONES;

EID: 33646124210     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850341     Document Type: Article

References (38)

1. Bacon RM, Mead PS, Kool JL, Postema AS, Staples JE. Lyme disease-United States, 2001-2002. MMWR Wkly. 2004;53:365-369.
2. Centers for Disease Control and Prevention. Lyme disease. Epidemiology. Available at: http://www.cdc.gov/ncidod/dvbid/lyme/epi.htm. Accessed June 22, 2005.
3. Thompson C, Spielman A, Krause PJ. Coinfecting deer-associated zoonoses: Lyme disease, babesiosis, and ehrlichiosis. Clin Infect Dis. 2001;33:676-685.
4. Krause PJ, Telford S, Spielman A, et al. Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illness. JAMA. 2006;275:1657-1660.
5. Shapiro ED, Gerber MA. Lyme disease. Clin Infect Dis. 2000;31:533-542.
6. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis. 2000;31(suppl 1):S1-S14.
7. Bujak DJ, Weinstein A, Dornbush RL. Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol. 1996;23:1392-1397.
8. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD). Neurology. 2003;60:1923-1930.
9. Steiner I. Treating post Lyme disease. Trying to solve one equation with too many unknowns. Neurology. 2003;60:1888-1889.
10. Weinstein A, Britchkov M. Lyme arthritis and post-Lyme disease syndrome. Curr Opin Rheumatol. 2002;14:383-387.
11. Shoemaker R, House D. Use of pioglitazone to prevent intensification of persistent symptoms following cholestyramine treatment of patients with post-Lyme syndrome [abstract]. Diabetes. 2002;51:A133.
12. Cartwright MJ, Martin SE, Donta ST. A novel neurotoxin (Bbtox 1) Borrelia burgdorferi. Presented at: Meeting of the American Society for Microbiology; May 1999; Chicago, Ill.
13. Hudnell HK. Chronic Lyme disease may be caused by toxins. Available at: Lyme Times/www.lymedisease.org. Accessed June 25, 2005.
14. Kjemtrup AM, Conrad PA. Human babesiosis: an emerging tick-borne disease. Int J Parasitol. 2000;30:1323-1337.
15. Weiss LM. Babesiosis in humans: a treatment review. Expert Opin Pharmacother. 2002;3:1109-1115.
16. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. 2000;343:1454-1458.
17. Gowda C. Natural antibodies to Plasmodium falciparum glycosylphospatidylinositol (GPI) in an area with seasonal malaria transmission [abstract]. Am J Trop Med Hyg. 2002;67:154.
18. Johnson L, Shoemaker RC. Treatment of horses with equine protozoal meningomyeloencephalitis (EPM) coinfected with Borrelia burgdorferi: a case series. Presented at: Third Annual Meeting, International Lyme and Associated Diseases Society; October 3, 2002; Princeton, NJ.
19. Shoemaker RC. MMP9, visual contrast sensitivity, C3A, C4A, and HLA DR: new diagnostic aids in acute and chronic Lyme disease. Presented at: 54th Annual Meeting of the American Society for Tropical Medicine and Hygiene; December 11-15, 2005; Washington, DC. Abstract/presentation 695.
20. Hartmann F, Müller-Marienburg H. Indifekter Neurotoxinnacgweis durch den visual contrast sensitivity test bei Patienten mit einer chronischen Boreliose. Med Welt. 2003;54:248-251.
21. Hudnell HK, Shoemaker RC. Sick building syndrome: possible association with exposure to mycotoxins from indoor air fungi. Available at: http://www.chronicneurotoxins.com/learnmore/latestAbstracts.cfm. Accessed July 24, 2005.
22. Pavia CS. Current and novel therapies for Lyme disease. Expert Opin Investig Drugs. 2003;12:1003-1016.
23. Schmidt P. New theory links neurotoxins with chronic fatigue syndrome, Lyme, MCS and other mystery illnesses. Available at: http://www.immunesupport. com/library/print.cfm. Accessed June 22, 2005.
24. Hartmann F, Müller-Marienburg H, Hopf-Seldel P. Uber die cholestyramine der chronischen Borreliose. Medizin. 2004;1:14-19.
25. Shoemaker RC. Markers for Chronic, Biotoxin-Associated Illness. Madison, Wisc: American Association for Chronic Fatigue Syndrome; 2004.
26. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med. 1986;99:22.
27. Questran® (cholestyramine) Powder [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 1999.
28. Shoemaker RC, Hudnell HK. Possible estuary-associated syndrome: symptoms, vision, and treatment. Environ Health Perspect. 2001;109:539-545.
29. Shoemaker RC, House D. A time study of sick building syndrome: chronic, biotoxin-associated illness from exposure to water-damaged buildings. Neurotox Teratol. 2005;27:29-46.
30. Shoemaker RC, Rash JM, Simon EW. Sick building syndrome in water-damaged buildings: generalization of the chronic, biotoxin associated illness paradigm to indoor toxigenic fungi. In: Eckardt J, ed. Bioaerosols, Fungi, Bacteria, Mycotoxins and Human Health. Albany, NY: Eastern New York Occupational & Environmental Health Center; 2005:66-77.
31. Shoemaker RC, Hudnell HK, House D. A new approach to chronic ciguatera illness and successful treatment with cholestyramine. Am J Trop Med Hyg. 2000;62(suppl):160-161.
32. Shoemaker RC, Hudnell HK. Exposure to freshwater lakes with resident toxigenic cyanobacteria, Cylindrospermopsis, is associated with a chronic illness. Poster presented at: Centers for Disease Control and Prevention National Conference on Pfiesteria; November 18, 2000; Stone Mountain, Ga.
33. Kyne L, Farrel RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001;30:753.
34. Gronczewski CA. Clostridium difficile colitis. Emedicine 2003. Available at: www.emedicine.com/med/topic3412.htm. Accessed July 12, 2005.
35. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother. 2001;45:2340.
36. Hudnell HK, House D, Schmid J, et al. Human visual function in the North Carolina clinical study on possible estuary-associated syndrome. J Toxicol Environ Health. 2001;62:575-594.
37. Shoemaker RC. Residential and recreational acquisition of possible estuarine associated syndrome: a new approach to successful diagnosis and treatment. Environ Health Perspect. 2001;109:791-796.
38. Shoemaker RC, House D. Characterization of chronic human illness associated with exposure to cyanobacterial harmful algal blooms predominated by Microcystis. Presented at: International Symposium on Cyanobacteria and Harmful Algal Blooms; September 6-7, 2005; Research Triangle Park, NC.